Therapeutic options for adult patients with previously treated immune thrombocytopenia – a systematic review and network meta-analysis

References

• British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(1):574–596.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–4207. doi: 10.1182/blood-2010-08-302984
   PubMed Web of Science ®Google Scholar
• Neunert C. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv. 2017;2017(1):400–405.
   Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med. 2000;160(11):1630–1638. doi: 10.1001/archinte.160.11.1630
   PubMed Web of Science ®Google Scholar
• Portielje JE, Westendorp RG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9):2549–2554. doi: 10.1182/blood.V97.9.2549
   PubMed Web of Science ®Google Scholar
• Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med. 2005;56:425–442. doi: 10.1146/annurev.med.56.082103.104644
   PubMed Web of Science ®Google Scholar
• Arai Y, Jo T, Matsui H, et al. Comparison of up-front treatments for newly diagnosed immune thrombocytopenia - a systematic review and network meta-analysis. Haematologica. 2018;103(1):163–171. doi: 10.3324/haematol.2017.174615
   PubMed Web of Science ®Google Scholar
• Caldwell DM, Ades A, Higgins J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Br Med J. 2005;331(7521):897–900. doi: 10.1136/bmj.331.7521.897
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691. doi: 10.1016/S0895-4356(97)00049-8
   PubMed Web of Science ®Google Scholar
• Higgins J, Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0. [Internet] March 2011. The Cochrane Collaboration, 2011. Available from: www.handbook.cochrane.org.
   Google Scholar
• Yang R, Li J, Jin J, et al. Multicentre, randomised phase III study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Br J Haematol. 2017;176(1):101–110. doi: 10.1111/bjh.14380
   PubMed Web of Science ®Google Scholar
• Tomiyama Y, Miyakawa Y, Okamoto S, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012;10(5):799–806. doi: 10.1111/j.1538-7836.2012.04695.x
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393–402. doi: 10.1016/S0140-6736(10)60959-2
   PubMed Web of Science ®Google Scholar
• Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641–648. doi: 10.1016/S0140-6736(09)60402-5
   PubMed Web of Science ®Google Scholar
• Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Eng J Med. 2007;357(22):2237–2247. doi: 10.1056/NEJMoa073275
   PubMed Web of Science ®Google Scholar
• Huang Y, Liu X, Chen Y, et al. The efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. Chin J Hematol. 2018;39(1):32–36.
   Google Scholar
• Shirasugi Y, Ando K, Miyazaki K, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized phase III clinical trial. Int J Hematol. 2011;94(1):71–80. doi: 10.1007/s12185-011-0886-8
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395–403. doi: 10.1016/S0140-6736(08)60203-2
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Eng J Med. 2006;355(16):1672–1681. doi: 10.1056/NEJMoa054626
   PubMed Web of Science ®Google Scholar
• Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9978):1653–1661. doi: 10.1016/S0140-6736(14)61495-1
   PubMed Web of Science ®Google Scholar
• Arnold DM, Heddle NM, Carruthers J, et al. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012;119(6):1356–1362. doi: 10.1182/blood-2011-08-374777
   PubMed Web of Science ®Google Scholar
• Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–3894. doi: 10.1182/blood-2013-07-514398
   PubMed Web of Science ®Google Scholar
• Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921–930. doi: 10.1002/ajh.25125
   PubMed Web of Science ®Google Scholar
• Grace RF, Neunert C. Second-line therapies in immune thrombocytopenia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):698–706. doi: 10.1182/asheducation-2016.1.698
   PubMed Web of Science ®Google Scholar
• Dolph M, Roy A, Bhor M, et al. A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists. J Comp Eff Res. 2018. DOI:10.2217/cer-2018-0034.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liang Y, Ai Y, et al. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. PloS one. 2018;13(6):e0198504. doi: 10.1371/journal.pone.0198504
   PubMed Web of Science ®Google Scholar
• Cooper K, Matcham J, Helme K, et al. Update on romiplostim and eltrombopag indirect comparison. Int J Technol Assess Health Care. 2014;30(1):129–130. doi: 10.1017/S0266462313000767
   PubMed Web of Science ®Google Scholar
• Newland A, Lee EJ, McDonald V, et al. Fostamatinib for persistent/chronic adult immune thrombocytopenia. Immunotherapy. 2018;10(1):9–25. doi: 10.2217/imt-2017-0097
   PubMed Web of Science ®Google Scholar
• Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood. 2009;113(14):3154–3160. doi: 10.1182/blood-2008-07-166439
   PubMed Web of Science ®Google Scholar
• Liu XG, Liu S, Feng Q, et al. Thrombopoietin receptor agonists shift the balance of Fcγ receptors towards inhibitory receptor IIb on monocytes in ITP. Blood. 2016;128(6):852–861. doi: 10.1182/blood-2016-01-690727
   PubMed Web of Science ®Google Scholar
• Neunert CE, Cooper N. Evidence-based management of immune thrombocytopenia: ASH guideline update. Hematology Am Soc Hematol Educ Program. 2018;2018(1):568–575.
   PubMed Web of Science ®Google Scholar
• Palandri F, Polverelli N, Sollazzo D, et al. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016;91(4):E267–E272. doi: 10.1002/ajh.24310
   PubMed Web of Science ®Google Scholar
• Li Z, Mou W, Lu G, et al. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93(1):91–98. doi: 10.1007/s12185-010-0753-z
   PubMed Web of Science ®Google Scholar
• Zhou H, Xu M, Qin P, et al. A multicenter randomized open-label study of rituximab plus rhTPO vs rituximab in corticosteroid-resistant or relapsed ITP. Blood. 2015;125(10):1541–1547. doi: 10.1182/blood-2014-06-581868
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–186. doi: 10.1182/blood-2009-06-225565
   PubMed Web of Science ®Google Scholar
• Jurczak W, Chojnowski K, Mayer J, et al. Avatrombopag, a novel oral thrombopoietin receptor agonist, demonstrates superiority to placebo for the treatment of chronic immune thrombocytopenic purpura in a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Blood. 2017;130(Suppl 1):17.
   Google Scholar
• Kelly K, Gleeson M, Murphy PT. Slow responses to standard dose rituximab in immune thrombocytopenic purpura. Haematologica. 2009;94(3):443–444. doi: 10.3324/haematol.2008.001396
   PubMed Web of Science ®Google Scholar
• Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25–33. doi: 10.7326/0003-4819-146-1-200701020-00006
   PubMed Web of Science ®Google Scholar
• Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989–5995. doi: 10.1182/blood-2011-11-393975
   PubMed Web of Science ®Google Scholar
• Wang S, Yang R, Zou P, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. Int J Hematol. 2012;96(2):222–228. doi: 10.1007/s12185-012-1124-8
   PubMed Web of Science ®Google Scholar